Drugs / PF-07985045
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06704724 | Dec 2024 → May 2026 | colorectal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07985045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06704724 ↗ |
| Route | Oral | “All participants in this study will take the study medication (PF-07985045) as pill by mouth.” NCT06704724 ↗ |